Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 8910 results

  1. Diclofenac–clotrimazole for Vulvovaginal candidiasis (VVC) [TSID 12053]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Ocrelizumab for treating relapsing–remitting multiple sclerosis in people 10 to 17 years [TSID12164]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Technologies to improve the detection of endometrial cancer

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  7. Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Xeomin (botulinum neurotoxin type A) for treating lower or upper limb spasticity in people 2 to 17 years [TSID12297]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Lanadelumab for preventing recurrent attacks of hereditary angioedema in people 2 years and over [TSID12298]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Infrared lasers for treating onychomycosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Noninvasive Vagus Nerve Stimulation For reactive airway disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation